Drug Type Small molecule drug |
Synonyms E-beraprost sodium, Esuberaprost, Esuberaprost potassium + [8] |
Target |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (17 Jan 1994), |
Regulation- |
Molecular FormulaC24H30O5 |
InChIKeyCTPOHARTNNSRSR-NOQAJONNSA-N |
CAS Registry94132-88-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10703 | - | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Occlusion of artery | KR | 17 Jan 1994 | |
Pulmonary Arterial Hypertension | KR | 17 Jan 1994 | |
Ulcer | KR | 17 Jan 1994 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Arterial Hypertension | Phase 3 | US | 10 Dec 2018 | |
Pulmonary Arterial Hypertension | Phase 3 | IL | 10 Dec 2018 | |
Neoplasms | Phase 3 | US | - |
Phase 3 | 112 | (Esuberaprost) | (kjouhtqnfy) = jioleepwnn ckncboioud (qafreiollt, yyeeqcammp - nzwpdjrauv) View more | - | 07 Sep 2020 | ||
Placebo+Esuberaprost (Placebo/Esuberaprost) | (kjouhtqnfy) = uyyxhrwubn ckncboioud (qafreiollt, ircuctpgej - qkefnjrkvj) View more | ||||||
Phase 3 | - | - | nawwjuqkok(ldvvnaoyjf) = Beraprost-314d relaxed constricted PAs with a 4-fold greater potency than beraprost tjesklfwkn (gnyszfvrbt ) View more | - | 01 Sep 2015 | ||